Actively Recruiting
Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease
Led by Shanghai Zhongshan Hospital · Updated on 2025-07-28
1670
Participants Needed
1
Research Sites
201 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The CANNON trial is a prospective, open-label, randomized, multicenter study designed to investigate rational hemoglobin target value in patients with anemia of non-dialysis chronic kidney disease treated with enarodustat. Eligible patients are randomly assigned 1:1 to the high-hemoglobin target group （hemoglobin of 13 g/dl）and low-hemoglobin target group （hemoglobin of 11 g/dl）and administered with enarodustat to achieve and maintain target hemoglobin over 96 weeks. The first primary endpoint was the difference of mean change in 36-Item Short Form Health Survey at week 24. The second primary endpoint was safety endpoints included time to major adverse cardiovascular + event (MACE+; all-cause mortality, myocardial infarction, stroke, and congestive heart failure requiring hospitalization) during 96 weeks.
CONDITIONS
Official Title
Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 75 years at the time of consent
- Body weight between 45 and 100 kg
- Diagnosed with chronic kidney disease stages 2 to 5 and not dialysis dependent
- Diagnosed with renal anemia with hemoglobin levels of 6 to 10 g/dL if untreated recently, or 8 to 12 g/dL if receiving certain treatments
- Serum ferritin above 100 bcg/L or transferrin saturation above 20% at screening
- Voluntarily agree to participate and sign informed consent
You will not qualify if you...
- Uncontrolled high blood pressure despite 4 weeks of treatment
- Severe proteinuria above specified thresholds depending on diabetes status
- Anemia caused by conditions other than chronic kidney disease
- History of autoimmune diseases that can cause anemia
- Active bleeding within 4 weeks before screening
- Serious thrombotic events within 6 months before screening
- Severe heart failure at screening
- Blood transfusion within 2 months before screening
- Use of immunosuppressants or immune therapies within 6 months before screening
- Expected need for dialysis, kidney transplant, or major surgery within 6 months
- Severe liver or biliary system problems at screening
- Receiving both ESA and roxadustat treatments at screening
- History of certain eye diseases requiring treatment
- Severe hyperparathyroidism
- Severe active infections
- Bedridden or difficulty walking, or history of certain blood clots
- History of active tumors
- Pregnant, breastfeeding, or not agreeing to contraception if female
- History of severe drug allergies or allergies to enarodustat
- Currently participating in another interventional clinical trial
- Other conditions judged unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200043
Actively Recruiting
Research Team
X
Xiaoqiang Ding
CONTACT
X
Xiaoyan Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here